StockNews.AI
WBA
StockNews.AI
210 days

WBA Investor News: Rosen Law Firm Encourages Walgreens Boots Alliance, Inc. Investors to Inquire About Securities Class Action Investigation - WBA

1. Rosen Law Firm investigating Walgreens for misleading business information. 2. Class action claims may further depress WBA's stock price. 3. DOJ lawsuit alleges Walgreens filled invalid prescriptions since 2012. 4. Walgreens stock price fell in aftermarket trading following the announcement.

5m saved
Insight
Article

FAQ

Why Bearish?

The ongoing investigation and DOJ lawsuit suggest potential liability, negatively affecting investor sentiment.

How important is it?

The investigation and lawsuit indicate serious risks which can substantially impact shareholder value.

Why Short Term?

Market reactions are likely immediate; ongoing legal issues may compound short-term volatility.

Related Companies

WBA
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) resulting from allegations that Walgreens may have issued materially misleading business information to the investing public. So What: If you purchased Walgreens securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=27235 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On January 17, 2025, the United States Department of Justice issued an announcement entitled "Justice Department Files Nationwide Lawsuit Alleging Walgreens Knowingly Filled Millions of Prescriptions that Lacked a Legitimate Medical Purpose." The announcement further stated that "[t]he government's complaint alleges that, from approximately August 2012 through the present, Walgreens knowingly filled millions of prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice." On this news, the price of Walgreens stock fell in aftermarket trading on January 17, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.      Phillip Kim, Esq.      The Rosen Law Firm, P.A.      275 Madison Avenue, 40th Floor      New York, NY 10016      Tel: (212) 686-1060      Toll Free: (866) 767-3653      Fax: (212) 202-3827      [email protected]      www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Related News